

## **Perrigo Confirms Settlement Of Generic Version Of Ofirmev® (acetaminophen) Injection Patent Litigation**

ALLEGAN, Mich., Nov. 28, 2012 [/PRNewswire/](#) -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle its Hatch-Waxman litigation relating to Ofirmev® (acetaminophen) injection brought by Cadence Pharmaceuticals, Inc. ("Cadence"). Under the terms of the settlement, Perrigo can launch a generic version of Ofirmev® (acetaminophen) injection on December 6, 2020, or earlier under certain circumstances. In addition, Perrigo has secured the right to be the sole authorized generic distributor should Cadence elect to launch an authorized generic product.

(Logo: <http://photos.prnewswire.com/prnh/20120301/DE62255LOGO> )

Ofirmev® (acetaminophen) injection is administered intravenously as a single or repeated dose therapy for the reduction of fever and the treatment of mild to severe pain with or without adjunctive opioid analgesics. Ofirmev® has annual sales of approximately \$42 million, as measured by Wolters Kluwer.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This settlement is another example of our long-term investment in extended product development. Perrigo continues its commitment to making quality healthcare more affordable for our customers."

From its beginnings as a packager of generic home remedies in 1887, Perrigo Company, based in Allegan, Michigan, has grown to become a leading global provider of quality, affordable healthcare products. The Company develops, manufactures and distributes over-the-counter ("OTC") and generic prescription ("Rx") pharmaceuticals, nutritional products and active pharmaceutical ingredients ("API") and is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. Perrigo's mission is to offer uncompromised "quality, affordable healthcare products", and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as certain other markets throughout the world, including Canada, China and Latin America. Visit Perrigo on the Internet (<http://www.perrigo.com>).

*Note:* Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's

subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

#### SOURCE Perrigo Company

For further information: Arthur J. Shannon, Vice President, Investor Relations and Communication, +1-269-686-1709, [ajshannon@perrigo.com](mailto:ajshannon@perrigo.com), or Bradley Joseph, Senior Manager, Investor Relations and Communication, +1-269-686-3373, [bradley.joseph@perrigo.com](mailto:bradley.joseph@perrigo.com)

---

<https://investor.perrigo.com/2012-11-28-Perrigo-Confirms-Settlement-Of-Generic-Version-Of-Ofirmev-acetaminophen-Injection-Patent-Litigation>